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A hallmark feature of atherosclerosis is that circulating
mononuclear cells adhere to the endothelium and mi-
grate into the subendothelial space. This adhesion is
mediated by molecules such as selectins that are ex-
pressed on the surfaces of both leukocytes and endo-
thelial cells. In this study, we have determined the role
of tissue-specific fucosyltransferase VII (FucT-VII), an
enzyme necessary for selectin ligand synthesis, in the
development of atherosclerosis. We adopted a scheme
of transplanting either FucT-VII/GFP bone marrow
into lethally irradiated low-density lipoprotein receptor
low density lipoprotein receptor mice or FucT-VII/
GFP bone marrow into FucT-VII/, low density li-
poprotein receptor double-mutant mice to evaluate the
roles of E- and P-selectin ligands versus L-selectin li-
gands, respectively, in diet-induced atherosclerosis.
GFP was used to track the transplanted cells. Our results
indicate that, compared with controls, selective disrup-
tion of E- and P-selectin ligand synthesis resulted in a
significant reduction in atherosclerosis. Selective dis-
ruption of L-selectin ligand production did not reduce
atherosclerosis as robustly as disruption of E- and P-
selectin ligands. In both groups, however, there was a
significant reduction in the accumulation of macro-
phages in the lesion. These studies indicate that selectin
ligands, particularly those for E- and P-selectins, play an
important role in the pathogenesis of atherosclerosis
by regulating macrophage accumulation in athero-
sclerotic lesions. (Am J Pathol 2009, 174:343–350; DOI:
10.2353/ajpath.2009.080036)
Macrophages play a key role in the development of ath-
erosclerosis. The presence of macrophage foam cells is
characteristic in all stages of lesions from early fatty
streak to advanced fibrofatty type.1 The importance of the
macrophage in atheroma formation has been underlined
in studies using osteopetrotic mice. These mice lack the
ability to generate macrophage-colony stimulating factor
(M-CSF); thus they are deficient in circulating monocytes
and tissue macrophages. Consequently, atherosclerotic
lesion development is inhibited in these mice when
crossed onto the atherosclerosis-prone apolipoprotein
E-deficient (ApoE/) or low-density lipoprotein receptor
deficient (LDLR/) background.2,3
Early in the development of atherosclerosis, circulating
mononuclear cells adhere to the endothelium and mi-
grate into the intima. Leukocyte adhesion and extravasa-
tion is mediated by molecules expressed on the surface
membranes of both leukocytes and endothelial cells.
These include the selectins and other adhesion mole-
cules such as intercellular adhesion molecule 1 (ICAM-1)
and vascular cell adhesion molecule 1 (VCAM-1).4–8
Three selectin adhesion molecules have been identi-
fied; E-, P-, and L-selectin. These adhesion molecules are
glycoproteins, characterized by an extracellular Ca2-
dependent lectin that binds to its respective ligands.9
E-selectin is primarily expressed on the surface of acti-
vated endothelial cells, where it mediates the binding of
circulating leukocytes. P-selectin is stored intracellularly
in -granules in platelets and Weibel-Palade bodies in
endothelial cells.10,11 After activation, it rapidly translo-
cates to the cell surface membrane. L-selectin is consti-
tutively expressed on many leukocyte types, where it
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mediates neutrophil, monocyte, and lymphocyte tether-
ing to and rolling on the endothelium.12,13
Selectin ligands that have been characterized include
P-selectin glycoprotein ligand-1 (PSGL-1), E-selectin li-
gand-1 (ESL-1), CD24, CD34, and others.14–16 All of
these ligands express glycans tipped with a fucosylated
and sialylated tetrasaccharide sialyl Lewis x (sLex), which
is critical for binding to the lectin domain of the selectins.
Addition of fucose to the appropriate underlying glycan to
generate the sLex tetrasaccharide in leukocytes and endo-
thelium is mediated by (1,3)fucosyltransferases (FucT)-IV
and -VII.17,18 A recent investigation determined the role of
FucT deficiency in atherogenesis using the ApoE/
mice.19 In this study, FucT-VII//ApoE/ mice devel-
oped less atherosclerosis than ApoE/ controls, sug-
gesting a role for systemic FucT-VII expression in medi-
ating the progression of this disease. In the current study,
we examined the importance of FucT-VII in the develop-
ment of atherosclerosis using the LDLR/ mouse model.
Using bone marrow transplantation, we generated chi-
meric mice with FucT-VII deficiency either in the leuko-
cytes or in all cells except the leukocytes to determine the
respective contributions of L-selectin or combined E- and
P-selectin ligands in atherogenesis.
Materials and Methods
Animals
LDL receptor-deficient mice backcrossed onto the
C57BL/6 background (LDLR/ mice) were purchased
from The Jackson Laboratories (Bar Harbor, ME) and
bred in-house. The generation and characterization of the
FucT-VII/ mice on the C57BL/6 background is detailed
elsewhere.17,18 Double-mutant mice were generated by
crossing LDLR/ mice with FucT-VII/ mice. In addi-
tion, FucT-VII/ mice were crossed with mice express-
ing enhanced green fluorescent protein (eGFP) on the
C57BL/6 background (The Jackson Laboratories). FucT-
VII/ mice were genotyped by polymerase chain reac-
tion as described elsewhere.17 The animal care commit-
tee at the Scripps Research Institute approved all
protocols pertaining to experimentation with animals. All
procedures used in this study conform to the Guide for
the Care and Use of Laboratory Animals published by the
National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
Generation of Chimeric Mice and General Study
Protocol
To determine the contribution of E- and P-selectin ligand
synthesis on atherogenesis, bone marrow transplantation
was used to disrupt either E- and P-selectin ligand synthesis
(by repopulating LDLR/ mice with marrow from FucT-
VII/eGFP mice, thereby retaining endothelial L-selectin
expression) or L-selectin ligand synthesis (by repopulating
FucT-VII/LDLR/ mice with FucT-VII/eGFP mar-
row). LDLR/ mice reconstituted with FucT-VII/eGFP
marrow served as the control group.
Male LDLR/ mice (8 to 10 weeks old) were lethally
irradiated and reconstituted with either FucT-VII/eGFP
(14 mice) or FucT-VII/eGFP (14 mice) marrow. Twelve
FucT-VII/LDLR/ mice were also lethally irradiated and
reconstituted with marrow from FucT-VII/eGFP mice. All
mice were allowed 4 weeks to recover, at which time they
were fed an atherogenic diet containing 15.8% fat, 1.25%
cholesterol, and no cholic acid (no. 94059; Harlan Tek-
lad, Madison, WI).20 Plasma samples were obtained by
retro-orbital sinus bleed at 4-week intervals, and plasma
cholesterol and triglyceride levels were measured. Cho-
lesterol content of each lipoprotein fraction was analyzed
from plasma pooled from all of the mice at each time
point using a fast protein liquid chromatography method
as previously described.21,22 After 12 weeks of high-fat
diet, the mice were sacrificed and perfused with phos-
phate-buffered saline (PBS) followed by formal-sucrose
(4% paraformaldehyde/5% sucrose in PBS, pH 7.4). The
hearts were removed and the organ was immersed in
formal-sucrose overnight before being embedded in
OCT (Sakura Finetek, Torrance, CA) and stored at
80°C until sectioning. The aortas were cleaned of con-
nective tissue and adventitial fat was removed. The iso-
lated aortas were then pinned open en face to allow
quantitation of atherosclerotic lesions on the luminal
surface.
Analysis of Atherosclerosis and
Immunohistochemistry
The extent of atherosclerosis in each mouse was as-
sessed by quantitating the lesions in the aortic root as
well as on the luminal surface of the aorta, the details of
which are described elsewhere.23 Serial (10 m) cryo-
sections of the aortic root were prepared and every fourth
section (for a total of four sections per heart) was stained
with Oil Red O, counterstained with Gill’s hematoxylin no.
1 (Fisher Scientific, Pittsburgh, PA), and digitally imaged
to quantitate total lesion area. To measure the extent of
macrophage infiltration into the lesion in the bone marrow
transplantation studies, sections were immunohisto-
chemically stained with a macrophage-specific antibody
(MOMA-2, 1:1000; Serotec, Raleigh, NC) and co-local-
ized with eGFP regions using a confocal microscope.
Areas of the sections stained positive with MOMA-2
antibody were selectively highlighted using computer-
assisted morphometry and quantitated as a percent-
age of MOMA-2-positive area throughout the entire
lesion area of the aortic sinus. Trichrome staining was
also performed on sections to determine collagen con-
tent of the lesion. En face aortas were stained with
Sudan IV and digitally imaged for analysis of lesion
area, expressed as a percentage of total aortic area,
as described elsewhere.23
Statistical Method
Data are presented as mean  SEM. Statistical signifi-
cance was determined using either t-test or two-way
analysis of variance followed by Bonferroni’s posttest as
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appropriate. In all cases, significance was determined as
P  0.05.
Results
Before performing the bone marrow transplantation stud-
ies, we crossed the FucT-VII/ mice with the LDLR/
mice. We then confirmed, as previously reported with
ApoE/ mice, that atherosclerosis was indeed reduced
in the LDLR/ mice with systemic FucT-VII deficiency
compared to the control LDLR/ mice.19 Aortic root le-
sion area was reduced 36.6% in FucT-VII/LDLR/ mice
compared to LDLR/ controls (FucT-VII /LDLR/
3.1  105  2.9  104 m2 versus LDLR/ 4.9  105 
4.7  104 m2, n  22, P  0.005). En face aorta lesion area
was reduced 57.5% in FucT-VII/LDLR/ mice com-
pared to LDLR/ controls (FucT-VII/LDLR/ 6.52 
0.53% versus LDLR/ 15.36  1.46%, n  23, P 
0.0001). However, total cholesterol levels were also re-
duced in the FucT-VII/LDLR/ mice by 22 to 33%
compared to LDLR/ mice throughout the course of the
high-fat diet treatment. We therefore investigated the role
of FucT-VII in atherosclerosis using bone marrow trans-
plantation. This technique allowed us to both control for
cholesterol level as well as to assess the selective con-
tribution of E- and P-selectin ligands versus L-selectin
ligands to atherosclerosis.
Selective disruption of E- and P-selectin ligand synthe-
sis was achieved by performing bone marrow transplan-
tation into irradiated LDLR/ mice with marrow cells
isolated from FucT-VII/ mice with one copy of the eGFP
gene to track the donor-derived leukocytes. This led to
disruption of selectin ligand synthesis on leukocytes that
would prevent the leukocytes from interacting with either
E- or P-selectin. The extent of atherosclerosis was signif-
icantly reduced in these mice compared with controls.
Aortic root lesion area was reduced 32.2% in LDLR/
mice reconstituted with FucT-VII/eGFP marrow com-
pared with LDLR/ mice reconstituted with eGFP mar-
row as controls (eGFP marrow 2.0  105  8.6  104
m2 versus FucT-VII/eGFP marrow 1.4  105 
1.1  104 m2, n  28, P  0.0005 by unpaired t-test)
(Figures 1 and 2). Similarly, there was a 37.8% reduc-
tion of the area of lesions on en face aortas in mice
reconstituted to lack E- and P-selectin ligand activity
compared with controls (eGFP marrow 5.88  1.22%
versus FucT-VII/eGFP marrow 3.66  0.38%, n 
28, P  0.05 by unpaired t-test) (Figure 3). As expected,
plasma cholesterol increased throughout time after intro-
duction of the high-fat diet. However, there was no sig-
nificant difference between plasma cholesterol concen-
trations in these two groups during the 12-week study
(Table 1). Collectively, these data suggest that produc-
tion of active E- and P-selectin ligands play a role in the
natural progression of atherosclerosis.
Selective disruption of active endothelial L-selectin li-
gand generation also reduced atherosclerotic progres-
sion compared to controls, although the reduction was
not as robust as with mice in which E- and P-selectin
ligand synthesis was disrupted. Aortic root lesion area
was reduced 29.7% in FucT-VII/LDLR/ mice recon-
stituted with eGFP marrow compared to LDLR/ con-
trols (eGFP marrow LDLR/ 2.0  105  8.6  104
Figure 1. Quantification of aortic root lesions stained positive for Oil Red O
in LDLR/ mice receiving GFP marrow (white bar), LDLR/ mice receiv-
ing FucT-VII/GFP marrow (gray bar), and FucT-VII/LDLR/ mice
receiving GFP marrow (black bar) fed a high-fat diet for 12 weeks. Data are
reported as the mean lesion area of four sections taken from the heart of each
animal every 40 m through the aortic valve. The mean  SEM is shown for
each group.
Figure 2. Representative slides of Oil Red O-stained aortic root sections from LDLR/ mice receiving GFP marrow (A), LDLR/ mice receiving FucT-VII/GFP
marrow (B), and FucT-VII/LDLR/ mice receiving GFP marrow (C) fed a high-fat diet for 12 weeks.
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m2 versus eGFP marrow, FucT-VII/LDLR/ 1.4 
105  1.2  104 m2, n  27, P  0.05 by unpaired t-test)
(Figures 1 and 2). Similarly, there was an 18.8% reduction
in lesioned aortic en face intimal surface in the mice
deficient in FucT-VII compared with controls, although
this difference was not statistically significant (eGFP
marrow LDLR/ 5.88  1.22% versus eGFP marrow,
FucT-VII/LDLR/ 4.77  0.77%, n  28, P  0.05)
(Figure 3). Plasma cholesterol was elevated at 8 weeks
compared with controls, however, at 4 and 12 weeks no
differences were observed (Table 1).
Fluorescence microscopy was used to confirm suc-
cessful bone marrow reconstitution. The presence of
eGFP cells in the vessel walls confirmed the presence
of donor cells 16 weeks after bone marrow transplant.
The presence of macrophages in aortic root lesions was
detected by immunohistochemistry, using the anti-
MOMA-2 antibody, calculating the percent lesion area
that was MOMA-2-positive. MOMA-2-positive staining
was reduced in mice lacking active E- and P-selectin
ligands on bone marrow-derived cells (eGFP marrow
46.18  5.54% versus FucT-VII/eGFP marrow
31.92  6.91%, n  12, P  0.01 by unpaired t-test). To
a lesser degree, disruption of active endothelial L-selec-
tin ligands also resulted in reduced area of MOMA-2-
positive staining (eGFP marrow LDLR/ 46.18 
5.54% versus eGFP marrow, FucT-VII/LDLR/
34.867  5.49%, n  12, P  0.01 by unpaired t-test)
(Figures 4 and 5). Representative photomicrographs in
Figure 4, D–F, also demonstrate that eGFP-positive leu-
kocytes are present in much greater number in the le-
sions of control mice (Figure 4D) compared with lesions
of mice with either E- and P-selectin ligand deficiency
(Figure 4E) or L-selectin ligand deficiency (Figure 4F).
These results indicate that all three selectin ligands par-
ticipate in the recruitment of macrophages to the athero-
sclerotic lesion, although our findings suggest that E- and
P-selectin ligands may play a slightly more significant
role than L-selectin ligand.
Discussion
Atherosclerosis is a disease mediated in large part by the
recruitment of monocytes/macrophages from the circula-
tion into the vessel wall, where they help drive the pro-
gression of lesion formation. Fundamental to this process
is the capture of the circulating cells by the endothelium,
a process in which the selectin family of adhesion mole-
cules are responsible for the initial rolling and tethering.
Subsequently, firm attachment followed by migration into
the subendothelial space occur mediated by the immu-
noglobulin adhesion molecules and the integrins.16 Pre-
viously, we and others have shown that ablation of the
FucT-VII gene results in dramatically reduced capacity of
neutrophils and monocytes to adhere to both E- and
P-selectins.17,18 These studies also showed that the ex-
pression of ligands themselves (such as PSGL-1) are not
reduced on the surfaces of leukocytes, indicating that
FucT-VII does not participate in the synthesis of the se-
lectin ligands but rather in activating them. Recently, our
group has demonstrated that systemic disruption of the
selectin pathway through the deletion of FucT-VII, neces-
sary for posttranscriptional modification of the selectin
ligands, results in the reduction of atherosclerosis in a
mouse model of atherosclerosis,19 and these findings are
in concordance with our own findings in the LDLR/
mouse atherosclerosis model.21–23 We have examined
the relative contributions of E- and P-selectin ligand and
L-selectin ligand production in the development of ath-
erosclerosis. Previous studies have indicated that each of
the selectins plays a unique role within the processes of
tethering and rolling, with L-selectin capturing leukocytes
from the flow in the vessel, E-selectin responsible for
rolling, and P-selectin a combination of both.24–27
The contributions of P- and E-selectin in mediating
atherosclerosis have been studied by several groups.
Using P-selectin/ mice crossed onto LDLR/ mice,
Johnson and colleagues28 showed a decrease in rolling
leukocytes as determined by intravital microscopy com-
pared with LDLR/ controls and a twofold reduction in
atherosclerosis at 8 weeks in P-selectin-deficient male
mice compared with controls. This early effect was attrib-
Figure 3. Quantification of total aortic lesion area stained positive for Sudan
IV in LDLR/ mice receiving GFP marrow (white bar), LDLR/ mice
receiving FucT-VII/GFP marrow (gray bar), and FucT-VII/LDLR/
mice receiving GFP marrow (black bar) fed a high-fat diet for 12 weeks.
Data are reported as percent lesion area compared to the total aortic surface
area for each animal. The mean  SEM is shown for each group.
Table 1. Plasma Cholesterol Values at 0, 4, 8, and 12 Weeks
Chimeric mice Fuc-T/GFP 3 LDLR/ GFP 3 LDLR/ GFP 3 Fuc-T/LDLR/
Week 0 221  12mg/dl, n  14 245  8mg/dl, n  14 260  7mg/dl, n  13
Week 4 886  44mg/dl, n  14 1027  70mg/dl, n  14 1138  110mg/dl, n  13
Week 8 816  35mg/dl, n  14 915  47mg/dl, n  14 1347  78mg/dl, n  13*
Week 12 1115  53mg/dl, n  14 1196  77mg/dl, n  14 1268  68mg/dl, n  13
All data are shown as mean  SEM. *P  0.05 as determined by two-way analysis of variance followed by Bonferroni’s post-test.
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utable to the importance of macrophage recruitment and
foam cell formation during the early stages of the dis-
ease. In that study, the authors were unable to ascertain
whether endothelial- or platelet-derived P-selectin was
the more important in contributing to atherosclerosis. In
part, this question is answered by our current study, in
which the contribution of selectin ligands on hematopoi-
etic cells that bind the selectins expressed by the endo-
thelium appears to be more important than selectin li-
gand expression on the endothelium. Dong and
colleagues29 took this approach a stage further by ex-
amining the combined contribution of both endothelially-
expressed selectins on atherosclerosis. Simultaneous
deficiencies of both E- and P-selectin resulted in a five-
fold reduction in the area of heart valve lesions in male
mice compared with LDLR deficiency alone at 8 weeks.
With the duration of the study being only 8 weeks, how-
ever, there were no measurable lesion areas on the en
face aortas for comparison.29 Eriksson and colleagues,30
used antibodies against the selectins to examine their
relative contributions to leukocyte adhesion and migra-
tion, as determined by intravital microscopy. Leukocyte
rolling was present in mice with atherosclerotic lesions
that were on a western diet but not in control mice on a
chow diet. E-selectin inhibition reduced, and P-selectin
inhibition abolished, leukocyte rolling in the aortas of
ApoE/LDLR/ mice on the western diet. E-selectin
inhibition also decreased leukocyte-endothelial contact
time and increased leukocyte rolling speed. P-selectin
was shown to be highly expressed on regions of the aorta
within the atherosclerotic lesion.
In common with these studies, we have shown that
inhibition of the endothelially-expressed selectins (via
disruption of selectin ligand synthesis in leukocytes)
leads to a decrease in the extent of the disease as
determined in both the aortic sinus and on the luminal
surface of the entire aorta. This is despite a potential
limitation of bone marrow transplantation in that not all of
the hematopoietic cells would be expected to stem from
the donor bone marrow, although in our study successful
reconstitution was determined by the presence of eGFP-
positive cells within the lesions. Despite this, there was
sufficient reduction of E- and P-selectin ligand production
by circulating leukocytes to reduce the progression of the
disease. Furthermore, it would be expected that second-
ary tethering would also be disrupted because of a re-
duction of L-selectin ligands on the leukocytes. Fuc-TVII
expression has been shown to be confined to bone mar-
Figure 4. Representative photomicrographs of aortic heart valve sections from LDLR/ mice receiving FucT-VII/GFP marrow (A, D), LDLR/ mice
receiving GFP marrow (B, E), and FucT-VII/LDLR/ mice receiving GFP marrow (C, F) fed a high-fat diet for 12 weeks. A–C: Black areas representing
regions of MOMA-2-positive macrophage staining. The black color represents MOMA-2-positive areas that were selected and highlighted using PhotoShop
outfitted with Chroma filter. This was done to demonstrate clearly the macrophages in the lesions. D–F: Representative examples of eGFP-positive cells in the
aortic root lesions to demonstrate the accumulation of bone marrow-derived mononuclear cells in atherosclerosis. Original magnifications: 100 (A–C); 250
(D–F).
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row and lung tissue, along with low levels in spleen,
salivary gland, and skeletal muscle, suggesting that
these effects are unlikely to be attributable to a systemic
effect in other tissues such as the kidney or the liver.31
By contrast, less work exists in the literature regarding
the role of L-selectin and atherosclerosis. Eriksson and
colleagues32 described the importance of L-selectin in
mediating the secondary capture of leukocytes in athero-
sclerotic vessels. A possible L-selectin ligand that would
be reduced in Fuc-TVII-deficient mice is endoglycan, a
molecule related to CD34 endoglycan has been shown to
be expressed on endothelial cells.33 Other traditional
L-selectin ligands, such as MadCAM-1, GlyCAM-1, and
MECA-79 have been shown to be important in smaller
vessels, such as high endothelial vessels, rather than the
aorta.34 Although deletion of the FucT-VII gene would
disrupt synthesis of most selectin ligands, other polysac-
charides have been identified as ligands for both P- and
L-selectin that do not contain sialic acids or fucose. Al-
though most of these have not been shown to have any
activity in vivo,35 these ligands include the heparan sul-
fate proteoglycans, such as collagen XVIII, which is likely
to be present in atherosclerotic plaques. Collagen XVIII
has been shown to act as a ligand for L-selectin, and may
help the transition between initial rolling and firm adhe-
sion,36–39 as well as mediate leukocyte-leukocyte adhe-
sion.40 Other proteoglycans have also shown activity as
L-selectin ligands, including versican, a chondroitin sul-
fate proteoglycan,41 although some studies have sug-
gested that this proteoglycan is more important in the
human vasculature than the mouse.42 Although sLex-
containing L-selectin ligands would have been disrupted
in our study, the reduction in atherosclerosis was not
significant. The presence of these alternate ligands that
are independent of FucT-VII is a possible reason for this
finding, although collagen XVIII has not been demon-
strated to mediate capture of leukocytes, suggesting that
selectins present on the surface of the endothelium play
a greater role in macrophage trafficking in the early
stages of atherosclerosis than those on the surface of
leukocytes. Although these proteoglycan ligands for L-
selectin have been shown to be important in the renal
vasculature,41,43 little exists in the literature on their role in
the development of atherosclerosis with regards to
selectins.
There is evidence that platelets can contribute to the
development of atherosclerosis. In vivo mouse models
have implicated endothelial P-selectin as playing a role in
this process, whereby platelets adhere to the endothe-
lium and then recruit circulating leukocytes,44 although
the contribution of platelet-mediated leukocyte recruit-
ment to the vasculature is not known. These interactions
are likely interrupted via the disruption of selectin ligand
synthesis in our study. Thus, it is possible that the reduc-
tion in atherosclerosis and in the accumulation of macro-
phages in the lesions of the LDLR/ mice reconstituted
with FucT-VII/eGFP marrow compared to LDLR/
mice reconstituted with eGFP marrow was attributable,
at least in part, to the disruption of P-selectin and the
subsequent adhesion of platelets to the endothelium.
It is not known why plasma cholesterol was lower in the
Fuc-TVII/LDLR/ compared to LDLR/ mice. The
fact that plasma cholesterol was not raised in the Fuc-
TVII
/
LDLR/ mice transplanted with wild-type bone
marrow cells indicates that it is the systemic expression
of FucTVII, rather than the leukocyte source of FucTVII,
that is responsible for the reduced plasma cholesterol
seen in the Fuc-TVII/LDLR/ mice. Although bone
marrow transplantations were performed with donor mar-
row cells that were LDLR/, we have shown in the past
that the expression of LDLR by the bone marrow-derived
cells does not affect either circulating cholesterol or the
extent of atherosclerosis in the LDLR/ mice.21 Thus, it
is unlikely that the LDLR expressed on bone marrow-
derived cells influenced the circulating cholesterol levels
in our bone marrow chimeric mice.
The observed decrease in cholesterol levels seen in
the Fuc-TVII/LDLR/ recipient mice at week 8 is un-
usual and difficult to explain. It appears from our data that
plasma cholesterol levels were raised earlier in these
mice than the other two groups. There are reports that
1,6-fucosyltransferase is involved with the LDLR-related
protein-1 (LRP-1), a scavenger receptor. Loss of fucosy-
lation after gene deletion impaired function of LRP-1, and
it is possible that a similar effect also occurred in the
Fuc-TVII/LDLR/ mice that led to an alteration in cho-
lesterol metabolism and increased plasma concentra-
tions.45,46 Additional work would be needed to further
explore the relationship between Fuc-TVII and plasma
cholesterol.
In summary, our studies suggest that the synthesis of
E- and P-selectin ligands, as mediated by the rate-limit-
ing enzyme FucT-VII, plays an important role in the patho-
genesis of atherosclerosis. These data suggest that
FucT-VII and the E- and P-selectin pathways may prove a
fruitful therapeutic target in the prevention or treatment of
atherosclerosis.
Figure 5. Quantification of total aortic root lesion area stained positive for
MOMA-2 in LDLR/ mice receiving GFP marrow (white bar), LDLR/ mice
receiving FucT-VII/GFP marrow (gray bar), and FucT-VII/LDLR/
mice receiving GFP marrow (black bar) fed a high-fat diet for 12 weeks.
Data are reported as percent MOMA-2-positive area compared to the total
lesion area in the aortic roots of each animal. The mean  SEM is shown
(n  6 for each group).
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17. Malý P, Thall A, Petryniak B, Rogers CE, Smith PL, Marks RM, Kelly
RJ, Gersten KM, Cheng G, Saunders TL, Camper SA, Camphausen
RT, Sullivan FX, Isogai Y, Hindsgaul O, von Andrian UH, Lowe JB: The
alpha(1,3)fucosyltransferase FucT-VII controls leukocyte trafficking
through an essential role in L-, E-, and P-selectin ligand biosynthesis.
Cell 1996, 86:643–653
18. Homeister JW, Thall AD, Petryniak B, Maly P, Rogers CE, Smith PL,
Kelly RJ, Gersten KM, Askari SW, Cheng G, Smithson G, Marks RM,
Misra AK, Hindsgaul O, von Andrian UH, Lowe JB: The
alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert collabora-
tive control over selectin-dependent leukocyte recruitment and lym-
phocyte homing. Immunity 2001, 15:115–126
19. Homeister JW, Daugherty A, Lowe JB: {alpha}(1,3)Fucosyltransferases
FucT-IV and FucT-VII control susceptibility to atherosclerosis in Apoli-
poprotein E/ mice. Arterioscler Thromb Vasc Biol 2004,
24:1897–1903
20. Boisvert WA, Black AS, Curtiss LK: ApoA1 reduces free cholesterol
accumulation in atherosclerotic lesions of ApoE-deficient mice trans-
planted with ApoE-expressing macrophages. Arterioscler Thromb
Vasc Biol 1999, 19:525–530
21. Boisvert WA, Spangenberg J, Curtiss LK: Role of leukocyte-specific
LDL receptors on plasma lipoprotein cholesterol and atherosclerosis
in mice. Arterioscler Thromb Vasc Biol 1997, 17:340–347
22. Boisvert WA, Spangenberg J, Curtiss LK: Treatment of severe hyper-
cholesterolemia in apolipoprotein E-deficient mice by bone marrow
transplantation. J Clin Invest 1995, 96:1118–1124
23. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA: A leukocyte
homologue of the IL-8 receptor CXCR-2 mediates the accumulation of
macrophages in atherosclerotic lesions of LDL receptor-deficient
mice. J Clin Invest 1998, 101:353–363
24. Lawrence MB, Bainton DF, Springer TA: Neutrophil tethering to and
rolling on E-selectin are separable by requirement for L-selectin.
Immunity 1994, 1:137–145
25. Alon R, Fuhlbrigge RC, Finger EB, Springer TA: Interactions through
L-selectin between leukocytes and adherent leukocytes nucleate roll-
ing adhesions on selectins and VCAM-1 in shear flow. J Cell Biol
1996, 135:849–865
26. Luscinskas FW, Ding H, Tan P, Cumming D, Tedder TF, Gerritsen ME:
L- and P-selectins, but not CD49d (VLA-4) integrins, mediate mono-
cyte initial attachment to TNF-alpha-activated vascular endothelium
under flow in vitro. J Immunol 1996, 157:326–335
27. Lawrence MB, Springer TA: Leukocytes roll on a selectin at physio-
logic flow rates: distinction from and prerequisite for adhesion
through integrins. Cell 1991, 65:859–873
28. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN,
Herz J, Hynes RO, Schaefer EJ, Wagner DD: Absence of P-selectin
delays fatty streak formation in mice. J Clin Invest 1997,
99:1037–1043
29. Dong ZM, Chapman SM, Brown AA, Frenette PS, Hynes RO, Wagner
DD: The combined role of P- and E-selectins in atherosclerosis. J Clin
Invest 1998, 102:145–152
30. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L: Direct viewing of
atherosclerosis in vivo: plaque invasion by leukocytes is initiated by
the endothelial selectins. FASEB J 2001, 15:1149–1157
31. Smith PL, Gersten KM, Petryniak B, Kelly RJ, Rogers C, Natsuka Y,
Alford III JA, Scheidegger EP, Natsuka S, Lowe JB: Expression of the
alpha(1,3)fucosyltransferase Fuc-TVII in lymphoid aggregate high
endothelial venules correlates with expression of L-selectin ligands.
J Biol Chem 2006, 271:8250–8259
32. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L: Importance of
primary capture and L-selectin-dependent secondary capture in leu-
kocyte accumulation in inflammation and atherosclerosis in vivo. J
Exp Med 2001, 194:205–218
33. Rosen SD: Ligands for L-selectin: homing, inflammation, and beyond.
Annu Rev Immunol 2004, 22:129–156
34. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K:
Lymphocyte recruitment into the aortic wall before and during devel-
opment of atherosclerosis is partially L-selectin dependent. J Exp
Med 2006, 203:1273–1282
35. Sperandio M: Selectins and glycosyltransferases in leukocyte rolling
in vivo. FEBS J 2006, 273:4377–4389
36. Varki A: Selectin ligands: will the real ones please stand up? J Clin
Invest 1997, 99:158–162
37. Norgard-Sumnicht K, Varki A: Endothelial heparan sulfate proteogly-
cans that bind to L-selectin have glucosamine residues with unsub-
stituted amino groups. J Biol Chem 1995, 270:12012–12024
38. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua
MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute
inflammation. Blood 1993, 82:3253–3258
39. Kawashima H, Watanabe N, Hirose M, Sun X, Atarashi K, Kimura T,
Shikata K, Matsuda M, Ogawa D, Heljasvaara R, Rehn M, Pihlajaniemi
T, Miyasaka M: Collagen XVIII, a basement membrane heparan sul-
fate proteoglycan, interacts with L-selectin and monocyte chemoat-
tractant protein-1. J Biol Chem 2003, 278:13069–13076
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